ArticleCancer management and research2023

Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report.

Zhisheng Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.